| Identification | Back Directory | [Name]
HP-625) | [CAS]
228113-66-4 | [Synonyms]
SHP625
SHP-625
HP-625)
SHP 625
Livmarli
Lopixibat
Maralixibat
Maralixibat?chloride
Lopixibat chloride
(LUM-001
Maralixibat chloride (Lopixibat chloride) | [Molecular Formula]
C40H56ClN3O4S | [MDL Number]
MFCD28502264 | [MOL File]
228113-66-4.mol | [Molecular Weight]
710.42 |
| Hazard Information | Back Directory | [Description]
Marilixibat chloride(228113-66-4) is an oral small-molecule ileal bile acid transporter (IBAT)
inhibitor developed by Mirum Pharmaceuticals and approved by
the USFDA for cholestatic pruritus in patients with Alagille
syndrome (ALGS). IBAT facilitates reabsorption of bile acids
from the ileum and is a key facilitator of bile acid enterohepatic
recirculation. Similar to surgical interruption of enterohepatic
recirculation, it was shown that inhibition of IBAT with 22
reduced pruritis in patients with ALGS.
| [Uses]
Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia[1][2]. | [in vivo]
Maralixibat chloride reduces elevations in sBA levels, improves liver function, and reduces liver tissue damage, in a rat partial bile duct ligation model of cholestasis[2]. | [storage]
Store at -20°C | [References]
[1] Shirley M. Maralixibat: First Approval [published correction appears in Drugs. 2021 Dec 6;:]. Drugs. 2022;82(1):71-76. DOI:10.1007/s40265-021-01649-0
[2] Mayo MJ, et al. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatol Commun. 2019 Feb 1;3(3):365-381. DOI:10.1002/hep4.1305 |
|
|